Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient

• Status: Completed
• Trial end date: 2021-08-18
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of study is to assess the efficacy of add-on estrogen pretreatment in GnRH antagonist protocol on oocyte retrieval as compared with GnRH antagonist protocol for patients with poor ovarian response Add-on estrogen pretreatment protocol is superior to none pretreatment GnRH antagonist protocol for the number of oocytes retrieval

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Reproductive & Genetic Hospital of CITIC-Xiangya
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Follicle Stimulating Hormone; Ganirelix; Polyestradiol phosphate

Criteria

Inclusion Criteria:Bologna criteria

• At least two of the following three features must be present:

1. Advanced maternal age (≥40 years) or any other risk factor for POR

2. A previous POR (≤3 oocytes with a conventional stimulation protocol)

3. An abnormal ovarian reserve test (i.e. antral follicle count < 5-7 follicles or AMH< 0.5 - 1.1 ng/mL)

Exclusion Criteria:

1. Age ≥45 years,

2. Patients who conducted PGD/PGS, and donor egg cycles were excluded.

3. Presence of unilateral ovary absence

4. Abnormal uterine deformity or structure.

5. Spontaneous abortion patients with three or more (including biochemical pregnancy abortion)

6. With other endocrine disease, ovulation disorders such as adrenal cortex function or thyroid dysfunction

7. Have assisted reproductive technology contraindications or pregnancy contraindication of patients